Transdermal 17β-estradiol for preventing postmenopausal bone loss [1]

Journal of the Chinese Medical Association

Volumn 70, Issue 10, 2007, Pages 464-465

  Lee, Wen Ling ^a,b   Chao, Hsiang Tai ^b   Wang, Peng Hui ^b  

^a Cheng Hsin Rehabilitation Center   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN;

BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HORMONAL THERAPY; HUMAN; LETTER; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MORBIDITY; MORTALITY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; VERTEBRA FRACTURE; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; NOTE;

ADMINISTRATION, CUTANEOUS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 36148937562     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(08)70041-8     Document Type: Letter

References (15)

1. Yang TS, Chen YJ, Liang WH, Chang CY, Tai LC, Chang SP, Ng HT. A clinical trial of 3 doses of transdermal 17β-estradiol for preventing postmenopausal bone loss: a preliminary study. J Chin Med Assoc 2007;70:200-6.
2. Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC. Standard and low-dose hormone therapy for postmenopausal women - focus on the breast. Taiwan J Obstet Gynecol 2007; 46:127-34.
3. Levine JP. Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone 2006;8:40-53.
4. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-8.
5. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, et al; WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-602.
6. Haney AF, Wild RA. Options for hormone therapy in women who have had a hysterectomy. Menopause 2007;14:592-7
7. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77.
8. Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Womens Health (Larchmt) 2007;16:600-31.
9. Takahashi K, Manabe A, Okada M, Kurioka H, Kanasaki H, Miyazaki K. Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas 2000;34:169-77.
10. Takahashi K, Okada M, Ozaki T, Kurioka H, Manabe A, Kanasaki H, Miyazaki K. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod 2000;15:1028-36.
11. Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. J Chin Med Assoc 1995;55:386-91.
12. Lindsay R, Hart DM, MacLean A, Garwood J, Clark AC, Kraszewski A. Bone loss during oestriol therapy in postmenopausal women. Maturitas 1979;1:279-85.
13. Terauchi M, Obayashi S, Aso T. Estriol, conjugated equine estrogens, and alendronate therapy for osteoporosis. Int J Gynaecol Obstet 2006;92:141-2.
14. Minaguchi H, Uemura T, Shirasu K, Sato A, Tsukikawa S, Ibuki Y, Mizunuma H, et al. Effect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open study. J Obstet Gynaecol Res 1996;22:259-65.
15. Reeker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007;40:843-51.